| Name | Title | Contact Details |
|---|---|---|
Jonathan Schantz |
Associate Director of R&D Operations | Profile |
Trevor Smith |
Vice President Preclinical R&D | Profile |
Rune Kjeken |
Executive Director, Research & Development | Profile |
Rune Kjeken |
Executive Director of Research & Development | Profile |
Kate Broderick |
Senior Vice President R&D | Profile |
Synosia Therapeutics is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SciMetrika is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.